MedPage Today on MSN
Triglyceride-Lowering Drug Gets FDA Nod for Rare Genetic Disorder
The small interfering RNA (siRNA) therapy, designed to reduce triglyceride levels by suppressing production of apolipoprotein ...
Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the nomination of APRTX-001 as its development candidate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback